BYQLOVI

Growth

clobetasol propionate

NDAOPHTHALMICSUSPENSION/DROPS
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7

Mechanism of Action

corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory…

Clinical Trials (5)

NCT05724446Phase 3Recruiting

Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

Started Dec 2022
NCT04246801Phase 3Completed

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)

Started Jun 2020
NCT04249076Phase 3Completed

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

Started Jun 2020
NCT01323673Phase 4Completed

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

Started Nov 2010
125 enrolled
Dermatitis, Chronic
NCT00828464Phase 4Completed

Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

Started Oct 2008
30 enrolled
Hand Dermatosis

Loss of Exclusivity

LOE Date
May 9, 2036
124 months away
Patent Expiry
May 9, 2036
Exclusivity Expiry
Mar 4, 2027

Patent Records (2)

Patent #ExpiryTypeUse Code
10588913
May 9, 2036
Product
11376262
May 9, 2036
Product
U-19